Multiple Tumor Types

Viewing Page 5 of 6 | Showing Results 41 - 50 of 54

Caris ctDNA Validation Project

The purpose of this study is to collect three tubes of blood for research use to validate (prove) the results of a new Laboratory Developed Test...

Michael Demeure, M.D.
  • Hoag Research
  • xSJH Southern California

A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)

A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors Harboring RET Alterations

Michael Demeure, M.D.
  • Hoag Research
  • xSJH Southern California

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

This trial will study Ladiratuzumab Vedotin (LV) to find out whether it is an effective treatment for different types of solid tumors and what side...

Rachel Sanborn, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic

A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment

This study is to compare the safety and effects of donepezil (Aricept) or if it decreases memory loss after receiving chemotherapy for breast...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability,...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

CriteriaPartial Inclusion Criteria:Patient with advanced or metastatic solid tumor and has disease progression or treatment intolerance after...

Ying Zhuo, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research

AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION

The purpose of this study is to find our what effects, good and/or bad, neratinib either by itself (monotherapy) or in combination with other drugs...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)

This is a Phase 1-2, open-label, multicenter, dose-finding, and proof of concept study for CX-2009 as monotherapy in subjects with advanced solid...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD 1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Patients with Advanced Malignancies

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 and to further evaluate its tolerability and efficacy in expansion...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic
Viewing Page 5 of 6 | Showing Results 41 - 50 of 54